Other Events ·
Adial Pharmaceuticals amended its Securities Purchase Agreement and Note Exchange Agreements to remove a penalty…
ADILAzora Therapeutics, Inc. (DE)
Adial Pharmaceuticals amended its Securities Purchase Agreement and Note Exchange Agreements to remove a penalty provision, reclassifying milestone warrant rights from liability to equity. This change restores compliance with Nasdaq Capital Market listing requirements by increasing stockholders' equity above the minimum threshold. The pro forma balance sheet shows total assets of $29.1 million and total liabilities of $6.2 million as of June 30, 2026. Adial Pharmaceuticals operates in the biopharmaceutical industry.